Ex-MD Anderson chief DePinho is helping launch another biotech — and he's sticking with familiar ground

Nicole DeFeudis

Editor

Years after co-founding SINE-focused Karyopharm and stirring up controversy at MD Anderson, Ronald DePinho is helping uncloak a new biotech targeting solute carrier transporter proteins …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ex-MD Anderson chief DePinho is helping launch another biotech — and he's sticking with familiar ground

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

J&J's Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trial

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Ex-MD An­der­son chief De­Pin­ho is help­ing launch an­oth­er biotech — and he's stick­ing with fa­mil­iar ground

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Ex-MD Anderson chief DePinho is helping launch another biotech — and he's sticking with familiar ground